Blueprint Sees Blockbuster Potential For Ayvakit In Systemic Mastocytosis With ISM Nod

The US FDA gave the drug a broad label in adults with indolent SM, without restrictions for disease severity or prior treatment, and Blueprint sees a potential $1.5bn market opportunity.